Preoperative Fibrinogen as a Biomarker Associated With Lymphovascular Space Invasion in Endometrial Carcinoma: A Cross-Sectional Study
Abstract
Objective: Elevated fibrinogen levels have been associated with tumor progression in multiple malignancies; however, their relationship with lymphovascular space invasion (LVSI) in endometrial carcinoma remains insufficiently characterized. This study investigated the association between preoperative fibrinogen levels and LVSI and evaluated its potential as a preoperative biomarker.
Materials and methods: This cross-sectional analytical study included 152 patients with histologically confirmed primary endometrial carcinoma treated between August 2018 and August 2023 at Bangabandhu Sheikh Mujib Medical University and selected private clinics in Dhaka, Bangladesh. Preoperative plasma fibrinogen levels were measured using the Claus method. LVSI status was determined through histopathological examination of surgical specimens. Multivariable logistic regression and receiver operating characteristic (ROC) curve analyses were performed.
Results: LVSI was identified in 30.3% of patients. Mean preoperative fibrinogen levels were significantly higher in patients with LVSI compared to those without (414.66 ± 117.94 mg/dL vs. 277.27 ± 89.34 mg/dL; p < 0.001). In multivariable analysis, each 100 mg/dL increase in fibrinogen was associated with a 2.34-fold increase in the odds of LVSI (adjusted odds ratio 2.34; 95% confidence interval 1.52–3.60;
p < 0.001). ROC analysis demonstrated good discriminatory performance (AUC 0.811; 95% CI 0.729–0.882). An optimal cut-off value of approximately 380 mg/dL yielded 65% sensitivity and 89% specificity.
Conclusion: Elevated preoperative fibrinogen levels are independently associated with LVSI in endometrial carcinoma and demonstrate good discriminatory performance. Fibrinogen may serve as a clinically accessible biomarker associated with LVSI and warrants further validation in larger prospective studies.
2. Milosevic B, Stojanovic B, Cvetkovic A, Jovanovic I, Spasic M, Stojanovic MD, et al. The Enigma of Mammaglobin: Redefining the Biomarker Paradigm in Breast Carcinoma. Int J Mol Sci. 2023;24(17):13407.
3. Zhou X, Wang H, Wang X. Preoperative CA125 and fibrinogen in patients with endometrial cancer: a risk model for predicting lymphovascular space invasion. J Gynecol Oncol. 2017;28(2):e11.
4. Ghezzi F, Cromi A, Siesto G, Giudici S, Serati M, Formenti G, et al. Prognostic significance of preoperative plasma fibrinogen in endometrial cancer. Gynecol Oncol. 2010;119(2):309–13.
5. Hefler-Frischmuth K, Lafleur J, Hefler L, Polterauer S, Seebacher V, Reinthaller A, et al. Plasma fibrinogen levels in patients with benign and malignant ovarian tumors. Gynecol Oncol. 2015;136(3):567–70.
6. Wu X, Yu X, Chen C, Chen C, Wang Y, Su D, et al. Fibrinogen and tumors. Front Oncol. 2024;14:1393599.
7. Lima LG, Monteiro RQ. Activation of blood coagulation in cancer: implications for tumour progression. Biosci Rep. 2013;33(5):e00064.
8. Falanga A, Marchetti M, Vignoli A. Coagulation and cancer: biological and clinical aspects. J Thromb Haemost. 2013;11(2):223-33.
9. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10(1):9–22.
10. Zhang Y, Li Z, Zhang J, Mafa T, Zhang J, Zhu H, et al. Fibrinogen: A new player and target on the formation of pre-metastatic niche in tumor metastasis. Crit Rev Oncol Hematol. 2025;207:104625.
11. Seebacher V, Polterauer S, Grimm C, Husslein H, Leipold H, Hefler-Frischmuth K, et al. The prognostic value of plasma fibrinogen levels in patients with endometrial cancer: a multi-centre trial. Br J Cancer. 2010;102(6):952–6.
12. Wang Z, Fan H, Wang W, Zheng G, Xiao Y, Guo H, et al. High Preoperative Plasma Fibrinogen Independently Predicts a Poor Prognosis in Patients with Nonmetastatic RCC. J Cancer. 2020;11(9):2401–7.
13. Cao P, Jiang L, Zhou LY, Chen YL. The clinical significance of preoperative serum fibrinogen levels and platelet counts in patients with gallbladder carcinoma. BMC Gastroenterol. 2021;21(1):366.
14. Behrouzi R, Barr CE, Crosbie EJ. HE4 as a Biomarker for Endometrial Cancer. Cancers (Basel). 2021;13(19):4764.
15. Wang F, Pang R, Shi S, Zhang Y. Construction and validation of a clinical risk model based on machine learning for screening characteristic factors of lymphovascular space invasion in endometrial cancer. Sci Rep. 2024;14(1):12624.
16. Tortorella G, Prashar A, Samson D, Kurnia S, Fogliatto FS, Capurro D, et al. Resilience development and digitalization of the healthcare supply chain: an exploratory study in emerging economies. Int J Logist Manage. 2023;34(1):130–63.
17. Zhang H, Ren P, Ma M, Zhu X, Zhu K, Xiao W, et al. Prognostic Significance of the Preoperative Albumin/Fibrinogen Ratio in Patients with Esophageal Squamous Cell Carcinoma after Surgical Resection. J Cancer. 2021;12(16):5025–34.
18. Ni J, Wang Y, Zhang H, Wang K, Song W, Luo M, et al. Combination of preoperative plasma fibrinogen and neutrophil-to-lymphocyte ratio to predict the prognosis for patients undergoing laparoscopic nephrectomy for renal cell carcinoma. Am J Cancer Res. 2022;12(8):3713–28.
19. Dai D, Chen B, Tang H, Wang B, Zhao Z, Xie X, et al. Nomograms for Predicting the Prognostic Value of
Pre-Therapeutic CA15-3 and CEA Serum Levels in TNBC Patients. PLoS One. 2016;11(8):e0161902.
20. Greten FR, Grivennikov SI. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity. 2019;51(1):27–41.
21. Peng Q, Zhu J, Zhang Y, Jing Y. Blood hypercoagulability and thrombosis mechanisms in cancer patients -A brief review. Heliyon. 2024;10(19):e38831.
22. Pang X, He X, Qiu Z, Zhang H, Xie R, Liu Z, et al. Targeting integrin pathways: mechanisms and advances in therapy. Signal Transduct Target Ther. 2023;8(1):1.
23. Kim SK, Cho SW. The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment. Front Pharmacol. 2022;13:868695.
24. Liu X, Shi B. Progress in research on the role of fibrinogen in lung cancer. Open Life Sci. 2020;15(1):326–30.
25. An Q, Liu W, Yang Y, Yang B. Preoperative fibrinogen-to-albumin ratio, a potential prognostic factor for patients with stage IB-IIA cervical cancer. BMC Cancer. 2020;20(1):691.
26. Bosse T, Peters EEM, Creutzberg CL, Jürgenliemk-Schulz IM, Jobsen JJ, Mens JWM, et al. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials. Eur J Cancer. 2015;51(13):1742–50.
27. Peters EEM, León-Castillo A, Smit VTHBM, Boennelycke M, Hogdall E, Hogdall C, et al. Defining Substantial Lymphovascular Space Invasion in Endometrial Cancer. Int J Gynecol Pathol. 2022;41(3):220–6.
28. Krenn-Pilko S, Langsenlehner U, Stojakovic T, Pichler M, Gerger A, Kapp KS, et al. An elevated preoperative plasma fibrinogen level is associated with poor disease-specific and overall survival in breast cancer patients. Breast. 2015;24(5):667–72.
| Files | ||
| Issue | Vol 20, No 1 (March 2026) | |
| Section | Original Articles | |
| Keywords | ||
| Endometrial Carcinoma Fibrinogen Lymphovascular Space Invasion Biomarker Risk Stratification | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
